Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives Consensus Rating of “Moderate Buy” from Analysts

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $6.8750.

Several analysts recently weighed in on the stock. Alliance Global Partners assumed coverage on shares of Sensus Healthcare in a report on Friday, March 6th. They issued a “buy” rating and a $7.50 target price for the company. Maxim Group dropped their target price on shares of Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Wall Street Zen downgraded shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a report on Tuesday, April 21st. Finally, Citigroup reissued a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th.

Sensus Healthcare Price Performance

Shares of NASDAQ SRTS opened at $3.61 on Friday. The company has a 50 day simple moving average of $4.04 and a 200-day simple moving average of $4.16. The company has a market capitalization of $59.42 million, a P/E ratio of -7.68 and a beta of 1.19. Sensus Healthcare has a 1 year low of $2.82 and a 1 year high of $5.92.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, May 7th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%. The company had revenue of $3.39 million during the quarter, compared to analyst estimates of $5.32 million.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Greenline Wealth Management LLC purchased a new stake in shares of Sensus Healthcare during the 4th quarter worth $513,000. Divisadero Street Capital Management LP lifted its position in shares of Sensus Healthcare by 39.5% during the 3rd quarter. Divisadero Street Capital Management LP now owns 452,897 shares of the company’s stock worth $1,422,000 after purchasing an additional 128,224 shares during the last quarter. Rothschild Wealth LLC purchased a new stake in shares of Sensus Healthcare during the 4th quarter worth $500,000. North Star Investment Management Corp. purchased a new stake in shares of Sensus Healthcare during the 1st quarter worth $500,000. Finally, Pacific Ridge Capital Partners LLC lifted its position in shares of Sensus Healthcare by 21.8% during the 4th quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock worth $2,781,000 after purchasing an additional 125,245 shares during the last quarter. Hedge funds and other institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.